Big Pharma is no longer interested in the manufacture and promotion of niche drugs such as those used in treatment of orphan diseases.
Several essential drugs have already been withdrawn from the market, leaving physicians and patients desperately waiting for vital treatments.
Disregard for such drugs is a consequence of low sales, high costs to maintain required regulatory, supply-chain and pharmacovigilance activities, which impact the contributions to the margin for stock exchange.
EFISCIENS is a global Niche and Specialties pharmaceutical company, with EU Corporate Headquarters in Pieta - Malta, with representative offices in Middle East and Asia.
EFISCIENS offers integrated marketing, distribution and logistics operations and holds more than 40 drug molecules.
EFISCIENS offers original molecules, well known to health care professionals that have proven efficacy and many are the last therapeutic options available to their patients.
EFISCIENS is engaged to protect the fundamental right for patients enduring hard pathologies to access a personal treatment.
EFISCIENS is currently focused on six therapeutic areas:
TRANSPLANTATION - ONCOLOGY - SUPPORTIVE CARE
CARDIOLOGY - ENDOCRINOLOGY - PSYCHIATRY
Most of patients under treatment, represent only 100 to 1500 patients by products and by country.
EFISCIENS works in close collaboration with Patients Associations, Professional Organisations, Institutions and Governmental Agencies to supply products when drugs are in shortage.
EFISCIENS respects the rights of patients and conducts its activity in order to comply with well-accepted standards of ethics, compliance and integrity.